Vivos Inc. Announces Expansion of IsoPet® Animal Cancer Division with Four New Veterinary Clinics Across the United States
The four facilities are not yet certified; state licensing and operational preparation remain necessary before treatment programs begin.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vivos (RDGL) is advancing four additional veterinary facilities through certification, licensing and onboarding to offer its IsoPet animal cancer treatment. The facilities are Veterinary Specialist Partners in Kentucky, Grace Veterinary Hospital in North Carolina, Malibu Coast Animal Hospital in California and Palm Beach Equine Clinic in Florida. Malibu Coast is progressing through California’s radioactive materials licensing process and could become the company’s first certified clinic in that state.
Each facility must meet applicable state radioactive materials licensing requirements, with approval timelines varying by jurisdiction. Vivos reports increasing demand across its existing certified network and anticipates additional recurring product sales as new clinics begin treatments. Domestic manufacturing is established at its Richland, Washington laboratory, which is focused on reducing production costs to help reach break-even.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Four additional facilities are advancing toward offering IsoPet, extending Vivos’ planned veterinary treatment network.
- Moderate pointIncreasing demand across existing certified clinics is reported by Vivos.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional recurring product sales are anticipated by Vivos as participating clinics complete certification and begin treatments.
- Minor pointDomestic IsoPet manufacturing is established at Vivos’ Applied Process Engineering Laboratory in Richland, Washington.
- Minor point. Forward-looking: it has not happened yet and may not happen.Production cost reductions are the laboratory’s focus to help Vivos reach break-even and advance toward profitability.
Negative
- Minor pointCertification, licensing and onboarding remain pending for the four additional facilities.
- Minor pointState radioactive materials approvals have varying timelines; regulatory and operational requirements take time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Kennewick, WA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is pleased to announce continued expansion of its IsoPet® Animal Cancer Division, with four additional veterinary facilities advancing through the certification, licensing, and onboarding process to offer IsoPet® cancer treatment.
The expansion represents an important step in Vivos’ strategy to broaden access to its innovative cancer therapy for animals while building the clinical infrastructure necessary to support increased treatment volumes, recurring product demand, and long-term revenue growth.
Four Veterinary Facilities Advancing Toward IsoPet® Certification
Veterinary Specialist Partners – Louisville, Kentucky
Led by co-founders Dr. Grace Clark and Dr. Scott Rizzo, both Doctors of Veterinary Medicine and Diplomates of the American College of Veterinary Internal Medicine, Veterinary Specialist Partners is an established specialty veterinary hospital offering advanced diagnostic, internal medicine, and oncology services. The addition of IsoPet® would complement the hospital’s existing capabilities and expand treatment options for companion animals facing challenging cancer diagnoses.
Grace Veterinary Hospital – Sherrills Ford, North Carolina
Under the leadership of Dr. Jean Tuttle, Grace Veterinary Hospital provides comprehensive veterinary medicine, rehabilitation, and patient-centered care. The hospital is progressing through IsoPet® training and onboarding, positioning the facility to introduce an additional localized cancer treatment option for pets throughout North Carolina and surrounding communities.
Malibu Coast Animal Hospital – Malibu, California
Founded by Dr. Dean Graulich, Malibu Coast Animal Hospital is an established veterinary practice offering comprehensive medical and surgical services. The hospital is advancing through California’s radioactive materials licensing process and is positioned to become Vivos’ first IsoPet® certified clinic in the state, representing an important opportunity to expand access to treatment on the West Coast.
Palm Beach Equine Clinic – Wellington, Florida
Led by board-certified equine surgeon Dr. Robert Brusie and his veterinary team, Palm Beach Equine Clinic is a recognized center for advanced equine medicine and surgery. The clinic is progressing through IsoPet® certification preparations, expanding Vivos’ opportunity to serve the equine oncology market, including horses requiring treatment for solid tumors and other localized cancers.
Building a Scalable Network Through Comprehensive Certification and Training
Establishing an IsoPet® certified veterinary facility requires a comprehensive process that extends well beyond a traditional clinic partnership. Because IsoPet® utilizes Yttrium-90, a therapeutic radioisotope, each participating facility must meet applicable state radioactive materials licensing requirements, with regulatory review and approval timelines varying by jurisdiction.
In parallel with licensing, Vivos has implemented a structured certification and onboarding program designed to prepare veterinary teams for the safe, effective, and consistent administration of IsoPet®. This process includes specialized radiation safety education, treatment protocol training, equipment preparation, practical application exercises, and coordinated support through the facility’s initial treatments.
While these regulatory and operational requirements take time, they are essential to establishing sustainable, revenue-generating treatment centers capable of delivering IsoPet® consistently and safely. Each new clinic represents an investment in the Company’s long-term clinical network, with the potential to generate recurring product demand as treatment programs become established.
Vivos continues to work closely with its veterinary partners to advance each facility through the required milestones as efficiently as possible, while maintaining the standards necessary for regulatory compliance, clinical readiness, and quality patient care.
Expanding Clinical Adoption and Long-Term Commercial Opportunity
Vivos is also seeing increasing demand across its existing certified clinic network as more pet owners seek IsoPet® treatment for their animals. This growing demand supports continued utilization at established clinics and reinforces the opportunity to expand access through new facilities.
The addition of these four facilities reflects growing interest in IsoPet® among veterinary professionals and strengthens Vivos’ presence across multiple U.S. regions and veterinary specialties.
As participating clinics complete certification and begin treating patients, Vivos anticipates increased treatment capacity, broader geographic access, and additional opportunities for recurring IsoPet® product sales.
With domestic IsoPet® manufacturing capabilities established at the Company’s Applied Process Engineering Laboratory (APEL) in Richland, Washington, Vivos is building the production and clinical infrastructure necessary to support its expanding veterinary network. APEL is focused on reducing production costs to help Vivos reach break-even and advance toward profitability.
The Company’s focus remains on converting its growing clinic pipeline into fully operational treatment centers, increasing utilization across its certified network, and establishing IsoPet® as a scalable, revenue-generating business within veterinary oncology.
The continued expansion of the IsoPet® Animal Cancer Division supports Vivos’ broader strategy of growing commercial revenue while advancing its Precision Radionuclide Therapy™ platform.
About Vivos Inc.
Vivos Inc. is developing advanced Yttrium-90-based Precision Radionuclide Therapy™ (PRnT) treatments for tumors in both animals (IsoPet®) and humans (RadioGel®). The Company is committed to advancing targeted cancer therapies through precise, localized delivery of therapeutic radiation. IsoPet® is commercially available for veterinary use through appropriately licensed and certified facilities in the United States.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of applicable securities laws. These statements include expectations regarding clinic certifications, regulatory approvals, future treatment activity, commercial expansion, and revenue growth. Actual results may differ materially from those expressed or implied due to regulatory timelines, operational requirements, market conditions, and other risks and uncertainties. Vivos Inc. undertakes no obligation to update forward-looking statements except as required by law.
Contact:
Vivos Inc. Investor Relations investors@vivosinc.com www.VivosInc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which new veterinary clinics are preparing to offer Vivos RDGL IsoPet treatment?
The four facilities are Veterinary Specialist Partners in Louisville, Kentucky; Grace Veterinary Hospital in Sherrills Ford, North Carolina; Malibu Coast Animal Hospital in Malibu, California; and Palm Beach Equine Clinic in Wellington, Florida. They are advancing through certification, licensing and onboarding rather than being announced as operational IsoPet treatment centers.
What training must veterinary clinics complete to offer Vivos IsoPet?
Vivos’ certification and onboarding program includes radiation safety education, treatment protocol training, equipment preparation and practical application exercises, with coordinated support through initial treatments. IsoPet uses Yttrium-90, a therapeutic radioactive material, so facilities must also meet applicable state radioactive materials licensing requirements.